MENU
AIMI
Stock ticker: OTC
PRICE
CHANGE
CAPITALIZATION
AIM ImmunoTech (AIMI) Ownership - Who owns AIM ImmunoTech?
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
6.14M
P/E Ratio
N/A
Total Cash
N/A
Projected Growth
N/A
Total Debt
N/A
Revenue
N/A
Risk (Beta)
1.27
Dividend Yield
N/A
Total Cash/Share
N/A
Total Debt/Equity
N/A
Revenue/Share
0.00 USD as % of share price
Fundamentals
AIMI
Capitalization
6.15M
P/E Ratio
N/A
Risk (Beta)
1.27
Dividend Yield
N/A
Total Cash
N/A
Total Cash/Share
N/A
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.00%
Revenue
N/A
ROE
N/A
Book Value
N/A
P/B Ratio
N/A
Cash Flow
N/A
Earnings
N/A
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
N/A
Current Ratio
N/A
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
N/A
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
N/A
Shares Held By Institutions
1.37M
Shares Outstanding - Current
72.3M
Total Liabilities
N/A
Total Volume MTD
N/A
Value
N/A
Gain YTD
-57.071
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders
Industry Biotechnology
Profile
Fundamentals
Details